How did Corcept Therapeutics' revenue and expenses trend in Q4 2024?
5/7/2025 10:30am
Aime
Corcept Therapeutics experienced a decline in revenue and an increase in expenses during Q4 2024 compared to the previous quarter.
Revenue Trend: The company's revenue decreased by approximately 4.33% to $675.04 million in Q4 2024, down from the previous quarter's revenue of $493.15 million. This indicates a contraction in sales and a potential impact on business performance.
Expense Trend: The Cost of Goods Sold remained at $2.96 million, which did not change significantly. However, the Selling, General, and Administrative Expenses increased to $83.37 million, up from the previous quarter's $70.3 million. This suggests that despite the revenue decline, operational costs have risen, potentially affecting profitability.
Net Income: The company reported a Net Income of $30.75 million in Q4 2024, which is a notable figure considering the revenue decline. This indicates that Corcept Therapeutics was able to maintain profitability despite the challenges in revenue growth.
1/2
CORT Revenue By Business
Date
Business Composition
Revenue By Business
20240101-2024
Product
675.04M
20240101-2024
Product
493.15M
20240101-2024
Product
310.60M
20240101-2024
Product
146.81M
20240101-2024
Product
146.81M
Name
Corcept TherapeuticsCORT
Corcept TherapeuticsCORT
Corcept TherapeuticsCORT
Corcept TherapeuticsCORT
Corcept TherapeuticsCORT
View null result
Explore
Screener
Best looking stocks that are MACD Golden Cross
Analysis
What is the trend of APOG's stock price?
Learn
Step 2: Macro context and catalyst, please provide the best sources, websites, and why, in French.
Wiki
For diabetes, what foods or drink are good to consume?